...
search icon
abbv-img

AbbVie Inc, Common Stock

ABBV

NYQ

$211.96

-$0.29

(-0.14%)

1D
Industry: Biotechnology Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$374.18B
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
89.1807
Volume info-icon
This is the total number of shares traded during the most recent trading day.
5.76M
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
3.07%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
0.60
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$149.56 L
$218.66 H
$211.96

About AbbVie Inc, Common Stock

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacture, commercialization, and sale of medicines and therapies worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, generalized pustular psoriasis, and pyoderma gangrenosum; Skyrizi to treat autoimmune diseases, erythrodermic psoriasis, generalized pustular psoriasis, and palmoplantar pustulosis; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta/Venclyxto to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic to treat neurologic diseases; Vraylar to treat schizophrenia, bipolar disorder, and depressive disorder; Duopa and Duodopa to treat Parkinson's disease; Ubrelvy to treat migraine; and Qulipta for episodic and chronic migraine, as well as other neuroscience products. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; and Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois. more

Industry: BiotechnologySector: Health Care

Returns

Time FrameABBVSectorS&P500
1-Week Return0.19%2.21%2.82%
1-Month Return5.52%-0.14%-7.12%
3-Month Return20.72%6.53%-4.35%
6-Month Return9.56%-5.33%-0.49%
1-Year Return20.25%1.07%8.67%
3-Year Return32.43%7.73%27.18%
5-Year Return207.99%85.88%147.38%
10-Year Return250.93%96.28%168.93%

Financials

Dec '20Dec '21Dec '22Dec '23Dec '245YR TREND
Total Revenue45.80B56.20B58.05B54.32B56.33B[{"date":"2020-12-31","value":78.9,"profit":true},{"date":"2021-12-31","value":96.8,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":93.56,"profit":true},{"date":"2024-12-31","value":97.04,"profit":true}]
Cost of Revenue15.39B17.45B17.41B20.41B16.90B[{"date":"2020-12-31","value":75.37,"profit":true},{"date":"2021-12-31","value":85.46,"profit":true},{"date":"2022-12-31","value":85.3,"profit":true},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":82.8,"profit":true}]
Gross Profit30.42B38.75B40.64B33.90B39.43B[{"date":"2020-12-31","value":74.84,"profit":true},{"date":"2021-12-31","value":95.35,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":83.42,"profit":true},{"date":"2024-12-31","value":97.02,"profit":true}]
Gross Margin66.41%68.96%70.00%62.42%69.99%[{"date":"2020-12-31","value":94.86,"profit":true},{"date":"2021-12-31","value":98.5,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":89.16,"profit":true},{"date":"2024-12-31","value":99.98,"profit":true}]
Operating Expenses17.86B19.86B21.83B21.15B30.29B[{"date":"2020-12-31","value":58.94,"profit":true},{"date":"2021-12-31","value":65.58,"profit":true},{"date":"2022-12-31","value":72.05,"profit":true},{"date":"2023-12-31","value":69.8,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Operating Income11.36B17.92B18.12B12.76B9.14B[{"date":"2020-12-31","value":62.72,"profit":true},{"date":"2021-12-31","value":98.93,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":70.41,"profit":true},{"date":"2024-12-31","value":50.43,"profit":true}]
Total Non-Operating Income/Expense(10.24B)(7.32B)(6.68B)(8.19B)(7.58B)[{"date":"2020-12-31","value":-1024500000000,"profit":false},{"date":"2021-12-31","value":-731900000000,"profit":false},{"date":"2022-12-31","value":-668400000000,"profit":false},{"date":"2023-12-31","value":-819100000000,"profit":false},{"date":"2024-12-31","value":-758100000000,"profit":false}]
Pre-Tax Income3.40B12.99B13.48B6.25B3.72B[{"date":"2020-12-31","value":25.21,"profit":true},{"date":"2021-12-31","value":96.38,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":46.38,"profit":true},{"date":"2024-12-31","value":27.57,"profit":true}]
Income Taxes1.22B1.44B1.63B1.38B(570.00M)[{"date":"2020-12-31","value":75,"profit":true},{"date":"2021-12-31","value":88.24,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":84.38,"profit":true},{"date":"2024-12-31","value":-34.93,"profit":false}]
Income After Taxes2.17B11.55B11.85B4.87B4.29B[{"date":"2020-12-31","value":18.35,"profit":true},{"date":"2021-12-31","value":97.5,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":41.14,"profit":true},{"date":"2024-12-31","value":36.18,"profit":true}]
Income From Continuous Operations4.62B11.55B11.85B4.87B4.29B[{"date":"2020-12-31","value":39.02,"profit":true},{"date":"2021-12-31","value":97.5,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":41.14,"profit":true},{"date":"2024-12-31","value":36.18,"profit":true}]
Income From Discontinued Operations-----[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Net Income4.62B11.54B11.84B4.86B4.28B[{"date":"2020-12-31","value":39,"profit":true},{"date":"2021-12-31","value":97.52,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":41.09,"profit":true},{"date":"2024-12-31","value":36.14,"profit":true}]
EPS (Diluted)10.5112.6813.8711.1110.12[{"date":"2020-12-31","value":75.78,"profit":true},{"date":"2021-12-31","value":91.42,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":80.1,"profit":true},{"date":"2024-12-31","value":72.96,"profit":true}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

ABBV
Cash Ratio 0.14
Current Ratio 0.66
Quick Ratio 0.55

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

ABBV
ROA (LTM) 8.26%
ROE (LTM) 62.29%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

ABBV
Debt Ratio Lower is generally better. Negative is bad. 0.98
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.02

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

ABBV
Trailing PE 89.18
Forward PE 17.27
P/S (TTM) 6.70
P/B 112.69
Price/FCF 56
EV/R 7.74
EV/Ebitda 29.26
PEG 0.44

FAQs

What is AbbVie Inc share price today?

AbbVie Inc (ABBV) share price today is $211.96

Can Indians buy AbbVie Inc shares?

Yes, Indians can buy shares of AbbVie Inc (ABBV) on Vested. To buy AbbVie Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in ABBV stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of AbbVie Inc be purchased?

Yes, you can purchase fractional shares of AbbVie Inc (ABBV) via the Vested app. You can start investing in AbbVie Inc (ABBV) with a minimum investment of $1.

How to invest in AbbVie Inc shares from India?

You can invest in shares of AbbVie Inc (ABBV) via Vested in three simple steps:

  • Click on Sign Up or Invest in ABBV stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in AbbVie Inc shares
What is AbbVie Inc 52-week high and low stock price?

The 52-week high price of AbbVie Inc (ABBV) is $218.66. The 52-week low price of AbbVie Inc (ABBV) is $149.56.

What is AbbVie Inc price-to-earnings (P/E) ratio?

The price-to-earnings (P/E) ratio of AbbVie Inc (ABBV) is 89.1807

What is AbbVie Inc price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of AbbVie Inc (ABBV) is 112.69

What is AbbVie Inc dividend yield?

The dividend yield of AbbVie Inc (ABBV) is 3.07%

What is the Market Cap of AbbVie Inc?

The market capitalization of AbbVie Inc (ABBV) is $374.18B

What is AbbVie Inc’s stock symbol?

The stock symbol (or ticker) of AbbVie Inc is ABBV

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top